Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...7879808182838485868788...858859»
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm, metatinib tromethamine (BMS-794833) / Simcere
    Journal:  BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway. (Pubmed Central) -  Mar 27, 2024   
    Recently, several TKIs, for instance regorafenib and cabozantinib, have showed clinical interest in treating osteosarcoma and target both vascular endothelial growth factor receptor (VEGFR) and mesenchymal epithelial transition factor (c-MET)...More importantly, BMS-794833 and anlotinib exerted synergistic therapeutic effects against osteosarcoma in vivo. Altogether, this study reveals a new (VEGFR)-targeting drug that can be combined with anlotinib for the treatment of osteosarcoma, which provides an important theoretical basis for overcoming anlotinib resistance.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Journal, PD(L)-1 Biomarker, IO biomarker, Immunomodulating:  Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma. (Pubmed Central) -  Mar 27, 2024   
    Herein, CaCO3-based nanoparticles coencapsulated with DOX, an immunogenic cell death (ICD) inducer, and evolocumab was developed to enhanced the efficacy of immunotherapy...Peritumoral delivery of DECP enhances the immune response of distant tumors and exhibits antitumor effects when combined with intravenous ?PD-L1 therapy in a bilateral tumor model. This study presents CaCO3-based nanoparticles with multiple immunomodulatory strategies against hepatocellular carcinoma by targeting PCSK9 inhibition and modulating immune homeostasis in the unfavorable TME.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  Targeting aberrant glycosylation to modulate microglial response and improve cognition in models of Alzheimer's disease. (Pubmed Central) -  Mar 27, 2024   
    Furthermore, we found that an increase in bisecting GlcNAc modified ICAM-1 resulted in impairment of microglial responses, and genetic inactivation of GnT-III protected against AD mechanistically by blocking the aberrant glycosylation of ICAM-1 and subsequently modulating microglial responses, including microglial motility, phagocytosis ability, homeostatic/reactive state and neuroinflammation. Moreover, by target-based screening of GnT-III inhibitors from FDA-approved drug library, we identified two compounds, regorafenib and dihydroergocristine mesylate, showing pharmacological potential leading to modulation of aberrant glycosylation and microglial responses, and rescue of memory and cognition deficits.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion, Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  EUCHARIS: European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (clinicaltrials.gov) -  Mar 27, 2024   
    P=N/A,  N=1939, Completed, 
    Moreover, by target-based screening of GnT-III inhibitors from FDA-approved drug library, we identified two compounds, regorafenib and dihydroergocristine mesylate, showing pharmacological potential leading to modulation of aberrant glycosylation and microglial responses, and rescue of memory and cognition deficits. Recruiting --> Completed | Trial completion date: Mar 2024 --> Nov 2023 | Trial primary completion date: Mar 2024 --> Nov 2023
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
    Trial completion date, Trial primary completion date:  ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) -  Mar 27, 2024   
    P2,  N=33, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Mar 2024 --> Nov 2023 | Trial primary completion date: Mar 2024 --> Nov 2023 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2024
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  Migraine Survey in Gulf Region (clinicaltrials.gov) -  Mar 26, 2024   
    P=N/A,  N=200, Not yet recruiting, 
    Not yet recruiting --> Active, not recruiting Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  A narrative review of the pharmaceutical management of osteoporosis. (Pubmed Central) -  Mar 26, 2024   
    Hormonal therapies are used if patients cannot tolerate bisphosphonates or denosumab or are refractory to these medications. Preventative measures for osteoporosis include tailored exercise and sufficient intake of calcium and vitamin D via diet or supplementation.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Trial initiation date:  Mechanistic Clinical Trial of PCSK9 Inhibition for AAA (clinicaltrials.gov) -  Mar 26, 2024   
    P1,  N=44, Not yet recruiting, 
    All the datasets used in this study can be freely available at ( https://github.com/Amar-Ajmal/Datasets-for-KRAS ). Initiation date: Feb 2024 --> Jul 2024
  • ||||||||||  CMAB807 (denosumab biosimilar) / 3SBio
    Trial completion date, Trial primary completion date:  Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia (clinicaltrials.gov) -  Mar 26, 2024   
    P3,  N=278, Recruiting, 
    Initiation date: Feb 2024 --> Jul 2024 Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
  • ||||||||||  MCC1 TCR - Fred Hutchinson Cancer Center, Affini / T Therap, Regeneron
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases, Immune cell:  ATTAC-MCC: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov) -  Mar 26, 2024   
    P1/2,  N=7, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=16 --> 7 | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Jan 2024
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Management of Vertebral Fragility Fracture in Older People: Recommendations from a Spanish Consensus of Experts. (Pubmed Central) -  Mar 25, 2024   
    Participants agreed on the administration of teriparatide for 24 months and then a switch to denosumab or bisphosphonates in patients at high risk of fracture...Although there was multidisciplinary agreement on diagnostic tests and non-pharmacological and pharmacological treatment in frail older people, therapeutic objectives should be individualized for every patient. In addition to the specific recommendations, close collaboration between the geriatrician and the primary care physician is essential for the optimal chronic management of frail patients with fragility fractures.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Review, Journal:  Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. (Pubmed Central) -  Mar 25, 2024   
    Furthermore, in all these asthma phenotypes, tezepelumab demonstrated higher efficacy in reducing exacerbations requiring hospitalizations or emergency department visits versus placebo. In patients with severe uncontrolled asthma, who commonly have multiple drivers of inflammation and disease, tezepelumab may modulate airway inflammation more extensively, as other available biologics block only specific downstream components of the inflammatory cascade.
  • ||||||||||  Review, Journal:  FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. (Pubmed Central) -  Mar 25, 2024   
    The next generation of small-molecule inhibitors, such as lirafugratinib and LOXO-435, and the FGFR2-specific antibody bemarituzumab are expected to have a reduced risk of hyperphosphataemia and the ability to overcome certain resistance mutations. In this Review, we describe the development and current clinical role of FGFR inhibitors and provide perspective on future research directions including expansion of the therapeutic indications for use of FGFR inhibitors, combination of these agents with immune-checkpoint inhibitors and the application of novel technologies, such as artificial intelligence.
  • ||||||||||  SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
    Retrospective data, Review, Journal, Metastases:  Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis. (Pubmed Central) -  Mar 25, 2024   
    In this Review, we describe the development and current clinical role of FGFR inhibitors and provide perspective on future research directions including expansion of the therapeutic indications for use of FGFR inhibitors, combination of these agents with immune-checkpoint inhibitors and the application of novel technologies, such as artificial intelligence. Current evidence supports SIRT treatment in patients with chemotherapy-refractory or chemotherapy-intolerant mCRC compared to newer oral agents, with comparable OS and low incidence of AEs.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
    P2 data, Clinical Trial,Phase II, Journal, PD(L)-1 Biomarker, IO biomarker:  Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. (Pubmed Central) -  Mar 25, 2024   
    P2
    Our data support further clinical development of the regorafenib-nivolumab combination as front-line treatment for uHCC and provide preliminary insights on immune biomarkers of response. ClinicalTrials.gov identifier: NCT04310709 .
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Phase classification, Trial primary completion date:  DeLLpro-300: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov) -  Mar 25, 2024   
    P1,  N=41, Active, not recruiting, 
    Clinicians should refer these patients to dermatologists to aid with management. Phase classification: P1b --> P1 | Trial primary completion date: Mar 2023 --> Aug 2025
  • ||||||||||  botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
    Trial primary completion date, Monotherapy:  C-800-25: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (clinicaltrials.gov) -  Mar 24, 2024   
    P2,  N=230, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Jan 2023 --> Jan 2025 Trial primary completion date: Jan 2024 --> Feb 2025
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal, Metastases:  Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. (Pubmed Central) -  Mar 24, 2024   
    P1b/2a
    Multi-omics data from the phase IIa patients (n?=?24 tumor/17 blood biopsy exomes; n?=?27 tumor transcriptomes) showed potential mechanisms of resistance (convergent evolution of HER2 activation, BRAFV600E), identified joint genomic/transcriptomic resistance features (ESR1 mutations, high estrogen receptor pathway activity, and a Luminal A/B subtype; ERBB2/BRAF mutations, high RTK/MAPK pathway activity, and a HER2-E subtype), and provided hypothesis-generating results suggesting that mTOR pathway activation correlates with response to the trial's therapy. Our results illustrate how genome and transcriptome sequencing may help better identify patients likely to respond to CDK4/6i therapies.